Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 44 clinical trials
  • 128 views
  • 23 Mar, 2022
  • 1 location
Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma (QUAD01)

Patients with unresectable or metastatic BRAF-mutant melanoma high-risk patients will be given 450 mg orally (PO) daily (QD) plus binimetinib 45 mg PO twice daily (BID) together with nivolumab

cancer
tumor cells
cytotoxic t-lymphocyte antigen 4
brain metastases
braf inhibitor
  • 5 views
  • 13 Apr, 2022
  • 1 location
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (InCITe)

This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in

cancer
international normalized ratio
hysterectomy
avelumab
ct scan
  • 27 views
  • 17 Jun, 2022
  • 4 locations
OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

treated with a combination of oral OKI-179 combined with the MEK inhibitor binimetinib.

NRAS
metastatic melanoma
liver metastasis
gilbert's syndrome
BRAF
  • 0 views
  • 04 Jul, 2022
Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer (OCEANII)

binimetinib 45 mg twice daily (BID) (Combo450) in adult Chinese participants with metastatic unresectable stage IV BRAF V600E mutant NSCLC, who are BRAF- and MEK-inhibitor treatment-naïve and are either

lung carcinoma
kidney function test
BRAF
measurable disease
large cell carcinoma
  • 0 views
  • 12 Jul, 2022
  • 8 locations
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

treatments involved in this study are: Active surveillance FOLFIRI treatment Nivolumab treatment Encorafenib/Binimetinib/Cetuximab treatment

folfiri regimen
cetuximab
folfox regimen
adjuvant chemotherapy
adjuvant therapy
  • 0 views
  • 25 Feb, 2022
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

First-in-human study to assess safety, tolerability, PK, and preliminary activity of PF-07284890 as a single agent and in combination with binimetinib in participants with BRAF V600-mutated

braf v600 mutation
BRAF
solid tumor
immunostimulants
braf inhibitor
  • 66 views
  • 04 Jun, 2021
  • 29 locations
PF-07284892 in Participants With Advanced Solid Tumors

with lorlatinib, encorafenib and cetuximab, or binimetinib and evaluate the pharmacokinetics, safety, and preliminary clinical activity of single agent and each combination therapy.

  • 0 views
  • 15 Mar, 2022
  • 7 locations
A Phase 1/2 Study of DCC-3116 as Monotherapy and Combination Therapy in Patients With MAPK Pathway Mutant Solid Tumors

This is a Phase 1/2, multicenter, open label, first in human (FIH) study of DCC-3116 as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in patients with advanced or

cancer
NRAS
lung cancer
lung carcinoma
braf v600e mutation
  • 0 views
  • 16 Jun, 2022
  • 5 locations
A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. (NAUTICALCRC)

Encorafenib is currently being developed (with or without binimetinib), in combination with cetuximab, for the treatment of adult patients with B-RAF proto-oncogene, serine/threonine kinase

  • 0 views
  • 13 Jul, 2022
  • 25 locations